Co-pending

Docket No. 00103.014US1 UC Case No. 1999-238-1

Clean Version of Pending Claims

USE OF ETODOLAC FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Applicant: Dennis A. Carson et al.
Serial No.: 09/360,020

1. (Twice Amended) A method of the reducing the viability of human leukemia cells sensitive to a compound of formula (I):



(I)

wherein R^1 is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R^2, R^3, R^4 and R^5 are the same or different and are each hydrogen or lower alkyl; R^6 is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R^7 is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C_1-C_3)alkyl(CO), wherein each alkyl is substituted with 0-2 (C_1-C_4) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino, or a pharmaceutically acceptable salt thereof, comprising administering an effective amount of the compound of formula (I) or the salt thereof to a human cancer patient afflicted with a leukemia.

6. (Amended) The method of claim 1 or 20 wherein the leukemia is chronic lymphocytic leukemia.

10. (Amended) The method of claim 1 or 20 wherein the compound of formula (I) is etodolac or R(-) etodolac.

12. (Amended) The method of claim 1 or 20 wherein the compound of formula (I) or the salt thereof is administered orally.

20. (Amended) A method comprising the killing of human leukemia cells sensitive to a compound of formula (I):



(I)

wherein R^1 is lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl or benzyl, R^2, R^3, R^4 and R^5 are the same or different and are each hydrogen or lower alkyl; R^6 is hydrogen, lower alkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R^7 is hydrogen, lower alkyl or lower alkenyl; X is oxy; Y is carbonyl or (C_1-C_3)alkyl(CO), wherein each alkyl is substituted with 0-2 (C_1-C_4) alkyl, and Z is hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino or phenylamino, or a pharmaceutically acceptable salt thereof, comprising administering an effective amount of the compound of formula (I) or the salt thereof to a human cancer patient afflicted with a leukemia.